These results implied that DXBTZ-CB[8]/CSA primarily reached and accumulated in the tumor via active CD44-targeting effect within 12 h post intravenous injection, while underwent obvious metabolic clearance from the tumor after 12 h. The gene discussed is CD44; the disease is neoplasm.